Good Lifestyle

When thePandemic of COVID-19 was officially declared on March 11, 2020, very little was understood on the virus, how it was propagated and when you could expect some sort of preventive treatment. However, with the approval of the end 2020 of two Pfizer and Moderna vaccines as a two-dose series, as well as the option at the single dose ofJohnson & Johnson-He had a lot of hope on the horizon. These vaccines are still working, but there is a growing concern that major changes can be essential.

RELATED:Dr. Faisci warns people vaccinated, he is "absolutely critical" to do it now.

Booster doses Have also been approved to help maintain vaccine protection, but scientists have expressed the need to understand how new and evolving variants of the disease affect the continued effectiveness of vaccines. According to a pre-version of a 6 April briefing of the United States Food and Drug Administration (FDA), theseMutations occur quickly, especially when using an immunocompromised person as a host. When combined with variable transmission rates and a large number of people infected, it becomes much more difficult for experts to predict the evolution of COVID.

To account for emerging strains, current COVID vaccines may need to be updated to ensure efficiency, depending on the FDA briefing. The issue will be addressed in vaccines and the meeting of the Advisory Committee on Related Organic Products Educated on April 6th.

"Although the full understanding of how the emerging variants SARS-COV-2 have an impact on the effectiveness of CIVID-19 vaccines, accumulated data suggest that the composition of vaccines may need to update to a given to guarantee the high level of efficiency. demonstrated in the first clinical trials of vaccine, "the FDA briefing is read.

In addition to discussing the "optimal stress composition" VVID vaccines, viral experts will also discuss how deformation changes need to be evaluated frequently, how to implement a formal process for selection of the vaccine strain, as well as possible. that the ideal time for booster doses in the general population and specific subpopulations.

As indicated by CNBC and noted in the FDA Briefing, theCurrently administered vaccines have been developed to target the SPIKE protein (allowing the virus to invade the target cells) of the original coronavirus strain, which emerged in 2019. Researchers seek to better understand how the new variants of Covid affecting The effectiveness of vaccines, as observing research studies have suggested a decrease in the response, particularly the current dominant variant, Omicron, said the FDA.

RELATED:For more information up to date, sign up for our daily newsletter.

While the blows closer to Moderna and Pfizer vaccines have been able to restore the effectiveness of the decrease in serious illness and hospitalization following the Omicron, it has been shown that the effects. Dispel over time, offering less protection against light diseases or even hospitalization, FDA reports. . This is also an urgent concern for those who are immunocomized.AE0FCC31AE342FD3A1346EBB1F342FCB

By February 18 briefing disease control and prevention centers (CDC),COVID protection After two doses of mRNA vaccine, namely Moderna and Pfizer, Wanes over time. When looking for effectiveness after a third dose during the predominant Omicron period, protection against emergency room visits or urgent care decreased from 87% to two months to 66% to four months. Effectiveness against Hospitalizations related to Covid also decreased from 91% to two months to 78% to four months.

Experts are also uncertain about the long period of certain variants will remain dominant, which further complicates the question of modification of vaccines and frequency. To answer questions, the FDA suggested referencing the "well-defined process" used to update vaccines against the season.

The World Health Organization (WHO) meets twice a year to discuss flu variants and make a recommendation, and the FDA committee makes its own recommendations for the United States, the document indicates. Although both entities normally have the same recommendations, according to CNBC, an update of the COVID vaccine can be made without the recommendation of WHO.

In its briefing, the FDA discussed the potential of a multivalent vaccine, which would target several peak proteins of different variants of COVID. This could offer advantages over a monovalent vaccine, which targets a single variant; However, any changes in vaccines will need to be supported by data from clinical trials, ensuring safety and efficiency, before they can be allowed by the FDA.

RELATED: I am stimulated and got Omicron - it was my worst symptom from afar .